Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Public ClinicalTrials.gov record NCT00139594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Study identification
- NCT ID
- NCT00139594
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis
- Industry
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Interventions
- licarbazepine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2004
- Primary completion
- Jun 30, 2007
- Completion
- Jun 30, 2007
- Last update posted
- Mar 27, 2017
2004 – 2007
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational site | La Palma | California | 20623 | — |
| Novartis Investigational Site | Kansas City | Kansas | — | — |
| Novartis Investigational Site | Shreveport | Louisiana | — | — |
| Novartis Investigational Site | Somerville | Massachusetts | — | — |
| Novartis Investigational Site | Farmington Hills | Michigan | — | — |
| Novartis Investigational Site | Staten Island | New York | — | — |
| Novartis Investigational Site | Madison | Tennessee | — | — |
| Novartis Investigational Site | Bellaire | Texas | — | — |
| Novartis Investigational Site | Dallas | Texas | — | — |
| Novartis Investigational Site | Verdun | Texas | — | — |
| Novartis Investigational Site | Bellevue | Washington | — | — |
| Novartis Investigational Site | Kirkland | Washington | — | — |
| Novartis Investigational site | West Allis | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00139594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00139594 live on ClinicalTrials.gov.